Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes

6 Jul 2020

Abstract excerpt

The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCAmut breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy
Share to Radiation Therapy and Dosimetry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32640708
DOI: 10.3390/jcm9072130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic ProbesPMID 32640708Read ↗

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and RadiotherapySemantic proximity Read ↗

Molecular Imaging of PARPSemantic proximity Read ↗

Molecular Imaging: PARP-1 and BeyondSemantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseSemantic proximity Read ↗

A novel <sup>18</sup> F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1Semantic proximity Read ↗

PARP inhibitors for anticancer therapySemantic proximity Read ↗

Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future OpportunitiesSemantic proximity Read ↗

A Radiotracer Strategy to Quantify PARP-1 Expression <i>In Vivo</i> Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapySemantic proximity Read ↗

PARP inhibitors combined with radiotherapy: are we ready?Semantic proximity Read ↗

Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligandSemantic proximity Read ↗

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic DrugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.